Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study

DOI: 10.1634/theoncologist.2018-0120

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text